Status: Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Participants needed: 884
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: GenmabUpdated: Jun 3, 2026Locations: 66
Eligibility criteria
Histologically or cytologically confirmed metastatic or unresectable solid malig... [+28]
History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that req... [+1]